Search results

1. Bispecific cytokine delivers for Innovent at last

   … “We are marginally more positive on IBI363 after ASCO 2025, but note [that] IL-2 is not high on the …

   
    

   Jacob Plieth
    
   - 10/23/2025 - 16:19

2. Few pancreatic Gleams of hope for Vyloy

   … Solid tumours Monotx Gastric cancer data at ASCO 2025 Source: OncologyPipeline. …

   
    

   Madeleine Armstrong
    
   - 10/16/2025 - 12:32

3. Takeda’s cancer prospects dim further

   … mimetic Polycythemia vera Ph3 Verify presented at ASCO 2025, filing due in H2 2025 Licensed from …

   
    

   Madeleine Armstrong
    
   - 10/03/2025 - 10:43

4. ESMO 2025 preview – Enhertu's early breast hat-trick

   … vs chemo + Herceptin + Perjeta Data presented at ASCO 2025; PDUFA date 23 Jan 2026 LBA18 …

   
    

   Batirtze Areitio
    
   - 09/30/2025 - 14:20

5. Zelgen’s DLL3 trispecific goes pivotal

   … Suzhou Zelgen China  ph2  data in 3rd-line SCLC at ASCO 2025: ORR 63% & 58% with 10mg & 30mg respectively; ph3 …

   
    

   Madeleine Armstrong
    
   - 10/02/2025 - 14:19

6. Joyo starts its first pivotal trial

   … x CD8 fusion protein, in relapsed cervical cancer.  At ASCO 2025 the company reported two partial responses in this …

   
    

   Batirtze Areitio
    
   - 09/25/2025 - 12:14

7. J&J goes straight into phase 3 in prostate

   … T-cell engager, possibly because phase 1 data presented at ASCO 2025 suggested that pasritamig could offer a safer … or chemo Pasritamig, uncontrolled Data presented at ASCO 2025 Source: OncologyPipeline & …

   
    

   Batirtze Areitio
    
   - 09/16/2025 - 14:56

8. World Lung 2025 – Ideaya challenges Zai Lab

   … ph1 Presentation venue World Lung 2025 ASCO 2025 ORR* 72% (52/72)** 51% (38/74)^ …

   
    

   Madeleine Armstrong
    
   - 09/09/2025 - 10:02

9. Novocure’s Lunar eclipse

   … + Abraxane, vs gemcitabine + Abraxane Data at ASCO 2025: OS 16.2mth vs 14.2mths; filed with FDA Aug 2025, …

   
    

   Madeleine Armstrong
    
   - 09/02/2025 - 15:02

10. BioNTech quietly drops Claudin6 work

    … Ph1/2 in solid tumours Disappointing results at ASCO 2025 BNT315 (GEN1055)* Ox40 agonist Hexabody …

    
     

    Madeleine Armstrong
     
    - 08/12/2025 - 10:34